Literature DB >> 29530603

Modulation of the endocrine transcriptional program by targeting histone modifiers of the H3K27me3 mark.

Marta Fontcuberta-PiSunyer1, Sara Cervantes2, Eulàlia Miquel3, Sergio Mora-Castilla4, Louise C Laurent4, Angel Raya5, Ramon Gomis6, Rosa Gasa7.   

Abstract

Posttranscriptional modifications of histones constitute an epigenetic mechanism that is closely linked to both gene silencing and activation events. Trimethylation of Histone3 at lysine 27 (H3K27me3) is a repressive mark that associates with developmental gene regulation during differentiation programs. In the developing pancreas, expression of the transcription factor Neurogenin3 in multipotent progenitors initiates endocrine differentiation that culminates in the generation of all pancreatic islet cell lineages, including insulin-producing beta cells. Previously, we showed that Neurogenin3 promoted the removal of H3K27me3 marks at target gene promoters in vitro, suggesting a functional connection between this factor and regulators of this chromatin mark. In the present study, we aimed to specifically evaluate whether targeting the activity of these histone modifiers can be used to modulate pancreatic endocrine differentiation. Our data show that chemical inhibition of the H3K27me3 demethylases Jmjd3/Utx blunts Neurogenin3-dependent gene activation in vitro. Conversely, inhibition of the H3K27me3 methyltransferase Ezh2 enhances both the transactivation ability of Neurogenin3 in cultured cells and the formation of insulin-producing cells during directed differentiation from pluripotent cells. These results can help improve current protocols aimed at generating insulin-producing cells for beta cell replacement therapy in diabetes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29530603     DOI: 10.1016/j.bbagrm.2018.03.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gene Regul Mech        ISSN: 1874-9399            Impact factor:   4.490


  5 in total

Review 1.  Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.

Authors:  Ammira Al-Shabeeb Akil; Esraa Yassin; Aljazi Al-Maraghi; Elbay Aliyev; Khulod Al-Malki; Khalid A Fakhro
Journal:  J Transl Med       Date:  2021-04-01       Impact factor: 5.531

2.  Epigenetic modifier Kdm6a/Utx controls the specification of hypothalamic neuronal subtypes in a sex-dependent manner.

Authors:  Lucas E Cabrera Zapata; María Julia Cambiasso; Maria Angeles Arevalo
Journal:  Front Cell Dev Biol       Date:  2022-10-04

Review 3.  Epigenetic Control of Pancreatic Regeneration in Diabetes.

Authors:  Shruti Balaji; Tiziana Napolitano; Serena Silvano; Marika Elsa Friano; Anna Garrido-Utrilla; Josipa Atlija; Patrick Collombat
Journal:  Genes (Basel)       Date:  2018-09-07       Impact factor: 4.096

Review 4.  Reading between the (Genetic) Lines: How Epigenetics is Unlocking Novel Therapies for Type 1 Diabetes.

Authors:  Ammira-Sarah Al-Shabeeb Akil; Laila F Jerman; Esraa Yassin; Sujitha S Padmajeya; Alya Al-Kurbi; Khalid A Fakhro
Journal:  Cells       Date:  2020-11-03       Impact factor: 6.600

5.  Using a new HSPC senescence model in vitro to explore the mechanism of cellular memory in aging HSPCs.

Authors:  Yongpin Dong; Chunni Guo; Wenfang Li; Lina Zhang; Wuxiong Zhou
Journal:  Stem Cell Res Ther       Date:  2021-08-09       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.